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abstract
A previous report suggested that 88% of individuals in the general population with total cholesterol
(TC) > 9.3 mmol/L have familial hypercholesterolaemia (FH). We tested this hypothesis in a cohort of
4896 UK civil servants, mean (SD) age 44 (±6) years, using next generation sequencing to achieve a
comprehensive genetic diagnosis. 25 (0.5%) participants (mean age 49.2 years) had baseline
TC > 9.3 mmol/L, and overall we found an FH-causing mutation in the LDLR gene in seven (28%) subjects.
The detection rate increased to 39% by excluding eight participants with triglyceride levels over
2.3 mmol/L, and reached 75% in those with TC > 10.4 mmol/L. By extrapolation, the detection rate would
be ~25% by including all participants with TC > 8.6 mmol/L (2.5 standard deviations from the mean).
Based on the 1/500 FH frequency, 30% of all FH-cases in this cohort would be missed using the 9.3 mmol/
L cut-off. Given that an overall detection rate of 25% is considered economically acceptable, these data
suggest that a diagnostic TC cut-off of 8.6 mmol/L, rather than 9.3 mmol/L would be clinically useful for
FH in the general population.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Familial Hypercholesterolaemia (FH) in its classical form is an
autosomal dominant disorder, characterised by increased plasma
levels of low-density-lipoprotein-cholesterol (LDL-C) and total
cholesterol (TC) from birth and premature cardiovascular events.
FH affects about 1/200 [1] to 1/500 [2] individuals of the Caucasian
population, with an estimated 1.8 to 4.5 million people affected in
Europe [3], and between 120,000e240,000 people in the UK with
heterozygous FH, of whom at least 75% are undiagnosed [4]. The
clinical diagnosis in the UK is based on the criteria of elevated TC
and LDL-C levels (>7.5 mmol/L and >4.9 mmol/L, respectively), and
family history of early coronary heart disease (CHD) and/or
elevated cholesterol levels, when patients are given a diagnosis of
possible FH (PFH), and the presence of clinical features such as
tendon xanthomas, when patients are given a diagnosis of deﬁnite
FH (DFH) [2]. In Europe, a scoring system developed in Holland [3]
is more widely used.
Recently, the need for implementation of universal or targeted
screening for FH to tackle the disease underdiagnosis and under-
treatment has been highlighted [1,3]. Early identiﬁcation of at-risk
individuals allows changes in lifestyle including dietary interven-
tion, and drug treatment, which have been shown to reduce cor-
onary atherosclerosis and to improve life expectancy [5e7].
Cascade testing using the family mutation to identify carrier rela-
tives unambiguously is a cost-effective method of ﬁnding addi-
tional FH patients, and has been used extensively in other countries
in Europe, most notably in Holland, for the last ﬁve years [8].
Improved identiﬁcation of FH cases has recently been included in
the new UK Department of Health Cardiovascular Outcomes
Strategy (https://www.gov.uk/government/publications/
improving-cardiovascular-disease-outcomes-strategy), and a
newly issued set of NICE Quality Standards (QS41) underline the
existing guidance for the diagnosis, cascade screening and * Corresponding author.
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criteria, individuals with TC > 7.5 mmol/L and/or LDL-C >4.9 mmol/
L should be assessed for a clinical diagnosis of FH. However, there is
concern that this proposed cut-off is toolowand will result in many
false positive diagnoses and a high workload for lipid clinics.
2. Hypothesis and methods
A previous study [10] suggested that 88% of the general popu-
lation in the US (age >40 years) withTC > 9.3 mmol/L (and/or LDL-C
>6.8 mmol/L) and normal triglycerides (TG < 2.3 mmol/L) are ex-
pected to have an FH-causing mutation. We aimed to test this
hypothesis using targeted next generation sequencing (NGS) (Illu-
mina TruSeq Custom Amplicon and MiSeq Illumina sequencer)
methods for genetic diagnosis of FH [11] in the Whitehall II pro-
spective cohort study (WHII) of British civil servants [12]. The
criteria of our standard variant calling pipeline were: coverage
 30 , minimum of ﬁve reads for an altered allele, Phred quality
 20, and a strand bias ﬁlter. To ensure that variants were not
missed a sensitive pipeline was used (coverage  15 , minimum of
two reads for an altered allele, Phred quality   zero, no strand bias
ﬁlter). Copy number variants (CNVs) were called using the Exo-
meDepth package [13]. All variants were conﬁrmed by Sanger
sequencing or for CNVs by MLPA [14]. The polygenic cause of
Fig. 1. The relationship of TC and FH mutation detection rate. A. TC distribution in WHII (n ¼ 4896). Red lines indicate the proposed TC cut-offs (7.5 mmol/L, 8.6 mmol/L and
9.3 mmol/L) and the proportion of the cohort above those cut-offs. Green arrow indicates the TC mean (5.9 mmol/L). One, two and three standard deviations (SD) to the right of the
mean are also marked. B. Percentage of adults with FH predicted by Williams et al. in comparison to FH mutation carriers in WHII and Oxford FH [18]. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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a 6-SNP genetic risk score [15,16].
3. Results
In the cohort of 4896 WHII participants recruited in 1985e99
(baseline characteristics shown in the Supplement Table S1), for
whom DNA samples were available, we identiﬁed 25 subjects
(0.5%) with a baseline TC > 9.3 mmol/L (TC distribution shown in
Fig. 1A). This group was sequenced for mutations in four FH genes
(LDLR, APOB, PCSK9 and LDLRAP1) and genotyped for six LDL-C-
associated SNPs (rs629301 in CELSR2, rs1367117 in APOB,
rs6544713 in ABCG5/8, rs6511720 in LDLR, and rs429358 and rs7412
in APOE). Causality of identiﬁed variants was thoroughly assessed
considering previously published studies and in silico tools [17].
Considering the conservative 1/500 frequency of FH, we would
expect 10 FH individuals in this cohort. An LDLR mutation,
including one CNV (Supplement Fig. S1) was found in 28% (n ¼ 7) of
sequenced individuals (Table 1), which accounted for 70% of the
estimated FH in WHII. The sensitive variant-calling pipeline did not
detect any additional mutations. The APOB p.R3527Q mutation,
which is known to account for about 5% of FH mutations in the UK
[18] was not found. However, our previous analysis of the WHII
cohort using the Metabochip [19] identiﬁed two carriers of the
p.R3527Q mutation. FH patients affected by the APOB mutation are
known to have lower TC/LDL-C than those with a defective LDL-
receptor [18,20]. In this case the two p.R3527Q mutation carriers
had TC of 9.3 mmol/L and 5.9 mmol/L and therefore they were
missed by the >9.3 mmol/L cholesterol cut-off criteria.
Polygenic hypercholesterolaemia is thought to account for the
majority of clinically diagnosed FH cases where no mutation can be
found [15,21]. Outof the 18 mutation negativeindividuals eight had
a 6-SNP LDL-C genetic risk score above the top quartile of the score
distribution, and 16 had a score in the top three quartiles of the
score, which is associated with a >95% likelihood of polygenic cause
of hypercholesterolaemia [16]. Using the genetic information, we
were therefore able to identify the likely genetic cause of their high
TC in 92% of sequenced individuals (seven monogenic and 16
polygenic). Of the unexplained two individuals, one had high TG
level (2.75 mmol/L), which could suggest a diagnosis of familial
combined hypercholesterolaemia. The polygenic cause of hyper-
cholesterolaemia in these patients should be considered when
designing a screening protocol for the proband's relatives, since the
efﬁciency of cascade testing in polygenic hypercholesterolaemia
patients is likely to be compromised in comparison to patients with
monogenic FH [15,16].
Mutation carriers in the studied cohort had signiﬁcantly higher
TC and signiﬁcantly lower TG levels than non-mutation carriers
(Table 2), which conﬁrms our previous ﬁndings that the FH muta-
tion detection rate correlates positively with pre-treatment TC and
negatively with pre-treatment TG [18].
We repeated the analysis after excluding individuals with
TG > 2.3 mmol/L (n ¼ 8, all were mutation negative), which led to
an increase in the percentage of subjects with TC > 9.3 mmol/L who
were FH-mutation carriers from 28% to 39% (Fig. 1B). We then
compared these results with a previously published cohort of FH
patients from an Oxford lipid clinic, who had been identiﬁed using
the standard Simon Broome criteria of TC > 7.5 mmol/L plus having
a family history of high cholesterol or premature CHD [2]. In this
sample of DFH and PFH patients overall the mutation the per-
centage of FH mutation carriers was 37% and among individuals
with TC > 9.3 mmol/L was 58%, which was signiﬁcantly higher than
in the WHII subjects (p ¼ 0.01 (c2)) (Fig.1B), reinforcing the utility
of family history information in identifying mutation carriers.
4. Discussion
Based on the classical frequency of heterozygous FH of 1/500 we
expected to ﬁnd 10 mutation carriers in the ~5000 subjects
included here, and successfully identiﬁed seven i.e. 70% of pre-
dicted. However, if the true frequency of FH in the UK is similar to
the 1/250 reported in Denmark [1], with this estimate supported by
the frequency of 1/217 of LDLR mutation carriers observed by
exome sequencing [22], our overall detection rate would be only
35% (i.e. 7 of the 20 expectedinthe 5000 subjects examined). While
it is possible that some mutation carriers were missed for technical
reasons in the next generation sequencing or bioinformatics
methods used, reducing the stringency of calling did not identify
any additional variants, which were conﬁrmed by Sanger
sequencing. It is most likely that some FH patients carrying “mild”
mutations (or with few common LDL-C raising variants i.e. a low 6-
SNP score) would not have been included in the selected 25 sub-
jects, as clearly shown by the exclusion of the two previously
identiﬁed APOB p.R3527Q carriers. For example, in the study of 101
mutation-positive FH patients from the Oxford lipid clinic [18]
mean TC in LDLR mutation carriers was 9.81 (±1.52) mmol/L, and
in the APOB p.R3527Q carriers was 9.12 (±0.85) mmol/L. In the
Oxford group, only 58% of mutation carriers would have been
detected using the 9.3 mmol/L TC threshold proposed by Williams
et al. [9].
The reason for the signiﬁcantly lower detection rate at a TC cut-
off of 9.3 mmol/L in WHII compared to that predicted by Williams
et al. (28% vs 88%) is unclear, but will be inﬂuenced by the distri-
bution of TC levels in the two samples (Utah mean
TC ¼ 5.3 ± 1.0 mmol/L vs. 5.9 ± 1.1 mmol/L in WHII), as well as
Table 1
LDLR mutations identiﬁed in the Whitehall II cohort. All variants were in a hetero-
zygous state and were conﬁrmed by Sanger sequencing or MLPA for CNVs.
Number of
carriers
DNA change
a Protein change Baseline total cholesterol
(mmol/L)
1 c.266G > A p.(Cys89Tyr) 11.6
1 c.1048C > T p.(Arg350
*) 12.4
1 c.1135T > C p.(Cys379Arg) 10.2
1 c.1238C > T p.(Thr413Met) 9.8
1 c.1444G > A p.(Asp482Asn) 9.4
1 c.1845 þ 11C > G Splicing changed 11.2
1 c.68 ?_940þ?del Deletion of exons
2 to6
11.9
a Sequence number using LDLR transcript: NM_000527.4 (numbered from ‘A’
(no.1) in the ‘ATG’ codon). Sequence density plots were used to determine the
presence of insertions and deletions and are presented in Supplementary material.
Table 2
Baseline characteristics (Mean ± SD) of the mutation positive and negative subjects.
Mutation þve
(n ¼ 7)
Mutation  ve
(n ¼ 18)
p
Age (years) 49.1 (±6) 49.2 (±5) 0.5
6-SNP LDL-C genetic score 0.67 (±0.1) 0.71 (±0.3) 0.3
Baseline TC (mmol/L) 10.9 (±1.1) 9.8 (±0.5) 0.007
Baseline TG (mmol/L) 1.3 (±0.7) 2.5 (±0.8) 0.004
Number of treated individuals
(%)
6 (86) 9 (50) 0.08
Post-treatment TC (mmol/L) 5.6 (±0.3) 5.7 (±1.1) 0.5
TC reduction after treatment
(%)
49 (±5) 41 (±12) 0.05
LDL-C, low-density-lipoprotein cholesterol; SNP, single nucleotide
polymorphism; þve, positive;  ve, negative.
Lipids concentrations were not normally distributed, and are presented as geo-
metric means with an approximate standard deviation in brackets.
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groups. While we do not have data on the number of FH-causing
mutation carriers that would have been detected if sampling had
been carried out at lower TC levels, extrapolation of the detection
rate data in Fig. 1 in the WHII sample where subjects with
TG > 2.3 mmol/L were excluded, suggests that roughly 15% of
subjects with TC > 7.5 mmol/L would be carriers. If an overall
detection rate of 25% were considered economically acceptable
(close to the reported detection rate in BRACA1/2 in women with a
family history of breast cancer [23] then a TC cut-off of >8.6 mmol/L
in 50 year old participants may be clinically useful. Although in this
study we were unable to assess the percentage of FH mutation
carriers in individuals with TC in the range of 8.6e9.3 mmol/L, we
estimated that using a cut-off of 2.5 standard deviations from the
TC mean of a screened population would achieve a ~25% mutation
detection rate (Fig. 1A). Based on the WHII cohort, lowering the TC
cut-off to 8.6 mmol/L would increase the number of individuals
who need the FH genetic test by three times (from 0.5% to 1.7% of
the population), and by 10 times if the Simon Broome FH cut-off
was used.
Taken together, in a general population opportunistic screening
situation, these ﬁndings may help to select individuals for an FH
DNA test using the TC measurement. However, the additional
assessment of family history and TG levels in potentially affected
individuals will signiﬁcantly improve the detection rate.
5. Limitations
Although we have previously demonstrated that NGS methods
for the detection of FH mutations are robust and more sensitive
than standard methods, including Sanger sequencing [24],w e
recognise that Sanger re-sequencing of the FH genes in our cohort
could provide additional evidence that no mutations were missed.
The 8.6 mmol/L TC cut-off was identiﬁed using an extrapolation
approach, which is subject to uncertainty. Lack of sequencing data
for individuals with TC   9.3 mmol/L prevents the analysis of the
true sensitivity/speciﬁcity of the FH diagnosis in these individuals.
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